In preclinical HCC models, pharmacological inhibition of FASN restores T-cell effector function, increases MHC I expression, enhances tumor antigen presentation, and cooperates with PD-1/PD-L1 blockade (details see Table 3) [173]. This evidence concerns the gene CD274 and neoplasm.